KIT Expression in Chromophobe Renal Cell Carcinoma: Comparative Immunohistochemical Analysis of KIT Expression in Different Renal Cell Neoplasms

American Journal of Surgical Pathology

Volumn 28, Issue 5, 2004, Pages 676-678

  Petit, Anna ^a   Castillo, Mireia ^a   Santos, Mónica ^a   Mellado, Begoña ^a   Alcover, Joan B ^a   Mallofré, Carme ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Chromophobe renal cell carcinoma; KIT; Renal cell carcinoma

Indexed keywords

IMATINIB; STEM CELL FACTOR;

ARTICLE; CANCER RECURRENCE; CARCINOGENESIS; CELL DIFFERENTIATION; COMPARATIVE STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; ONCOCYTOMA;

EID: 2342529824     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000478-200405000-00017     Document Type: Article

References (30)

1. Akhtar M, Kardar H, Linjawi T, et al. Chromophobe cell carcinoma of the kidney: a clinicopathologic study of 21 cases. Am J Surg Pathol. 1995;1245-1256.
2. Beghini A, Peterlongo P, Ripamonti CB, et al. C-kit mutations in core binding factor leukemias. Blood. 2000;95:726-727.
3. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000; 295:139-145.
4. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612-624.
5. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8:3034-3038.
6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
7. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
8. Ferger F, Ribadeau Dumas A, Leriche L, et al. Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts. Int Arch Allergy Immunol. 2002;127:110-114.
9. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925-932.
10. Hirota S, Isozaki K, Moriyama Y, et al. Gain of function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577-580.
11. Galli SJ, Zsebo KM, Geissler EN. The kit ligand, stem cell factor. Adv Immunol. 1994;55:1-96.
12. Kovacs A, Kovacs G. Low chromosome number in chromophobe renal cell carcinomas. Genes Chromosomes Cancer. 1992;3:267-268.
13. Kovacs G, Akhtar M, Beckwith BJ, et al. The Heidelberg classification of renal cell tumours. J Pathol. 1997;183:131-133.
14. Mathers ME, Pollovk AM, Marsh C, et al. Cytokeratin 7: a useful adjunct in the diagnosis of chromophobe renal cell carcinoma. Histopathology. 2002;40:563-567.
15. Nagy A, Wilhelm M, Sukosd F, et al. Somatic mitochondrial DNA mutations in human chromophobe renal cell carcinomas. Genes Chromosomes Cancer. 2002;35:256-260.
16. Ortmann M, Vierbuchen M, Fisher R. Renal oncocytoma: lectin and immunohistochemical features indicating an origin from the collecting duct. Virchows Arch B. 1988;56:175-184.
17. Peggs K, Mackinnon S. Imatinib mesylate: the new gold standard for treatment of chronic myeloid leukemia. N Engl J Med. 2003;348:1048-1050.
18. Renshaw A, Henske E, Loughlin K, et al. Aggressive variants of chromophobe renal cell carcinoma. Cancer. 1996;78:1756-1761.
19. Speicher MR, Schoell B, du Manoir S, et al. Specific loss of chromosomes 1, 2, 6, 10, 13, 17 and 21 in chromophobe renal cell carcinomas revealed by comparative genomic hybridization. Am J Pathol. 1994;145:356-364.
20. Störkel S, Steart PV, Drenckhahn D, et al. The human chromophobe cell renal carcinoma: its probable relation to intercalated cells of the collecting duct. Virchows Arch B. 1989;56:237-245.
21. Thoenes W, Störkel S, Rumpelt HJ. Human chromophobe cell renal carcinoma. Virchows Arch B (Cell Pathol.) 1985;48:207-217.
22. Thoenes W, Störkel S, Rumpelt HJ, et al. Chromophobe cell renal carcinoma and its variants: a report on 32 cases. J Pathol. 1988;155:277-287.
23. Thomsen L, Robinson TL, Lee JC, et al. Interstitial cells of Cajal generate a rhythmic pacemaker current. Nat Med. 1998;4:848-851.
24. Tian Q, Frierson HF Jr, Krystal GW, et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol. 1999;154:1643-1647.
25. Tsuura Y, Hiraki H, Watanabe K, et al. Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch. 1994;424:135-141.
26. Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358:1421-1423.
27. Vliagoftis H, Worobec AS, Metcalfe DD. The protooncogene c-kit and c-kit ligand in human disease. J Allergy Clin Immunol. 1997;100: 435-440.
28. Yamazaki K, Sakamoto M, Ohta T, et al. Overexpression of KIT in chromophobe renal cell carcinoma. Oncogene. 2003;22:847-852.
29. Yarden Y, Kuang WJ, Yang-Feng T, et al. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987;6:3341-3351.
30. Young A, Amin M, Moreno C, et al. Expression profiling of renal epithelial neoplasms. Am J Pathol. 2001;158:1639-1651.